

Dear Bureau members,

## **Request for scientific Endorsement**

### **Expert Perspective Consensus Meeting on “Clinical Practice and Application of Double Plasmafiltration Molecular Adsorption System (DPMAS) in Liver Diseases”**

#### **1. Introduction and Background**

We are organizing an **Expert Perspective Consensus Meeting** focused on the **clinical practice and application of Double Plasmafiltration Molecular Adsorption System (DPMAS)** in liver diseases. DPMAS has emerged as a critical modality in the field of artificial liver support systems, with extensive clinical experience accumulated in China and growing interest from centers across Europe, Asia, and Latin America. Despite its increasing utilization, there remains a lack of standardized international guidance on its optimal use, patient selection, treatment protocols, and monitoring strategies.

This consensus initiative aims to bring together leading international experts in hepatology, intensive care, nephrology, and liver transplantation to develop a structured expert perspective that will serve as a practical reference for clinicians worldwide.

#### **2. Objectives of the Consensus Meeting**

The primary objectives of this meeting are:

- To review and evaluate existing clinical evidence on the efficacy and efficiency of DPMAS in various liver disease indications, including acute liver failure (ALF), acute-on-chronic liver failure (ACLF), liver transplantation, and other relevant conditions.
- To establish consensus recommendation on key clinical questions, including:
  - Clinical efficacy and impact on survival, prognostic scores, organ function, and biomarkers.
  - Optimal timing for initiation and termination of DPMAS therapy.
  - Treatment parameters (e.g., plasma volume, blood flow rate, frequency).
  - Combination treatment strategies and sequencing.
  - Monitoring, safety, anticoagulation, and contraindications.
- To provide a foundational academic framework for the development of an international hepatology benchmark scientific community.

#### **3. Participating Experts and Organizational Structure**

The consensus meeting brings together a distinguished, multidisciplinary group of international experts from Europe, Asia, the Latin America. The expert panel includes leaders in hepatology, intensive care, nephrology, and liver transplantation.

#### **Executive Leadership:**

- **Prof. Faouzi SALIBA** – Chair (France)  
Head, Intensive Care Unit, Hepato-biliary Centre and Liver Transplant Unit; Board Member, Chronic Liver Failure (CLIF) Consortium – EASL
- **Prof. Jinjun CHEN** – Executive Chair (China)  
Director, The Second Affiliated Hospital of Chongqing Medical University;  
Chairman, Liver Disease Branch of Guangdong Precision Medicine Application Society
- **Prof. Yuemin NAN** – Advisor (China)  
Director, Hebei Medical University Third Hospital; Chairman, Hepatology Branch, Chinese Medical Association

#### **Expert Panel Includes:**

- **Prof. Paolo ANGELI** (Italy) – Head, Unit of Internal Medicine and Hepatology, University of Padova; Editor-in-Chief, *Journal of Hepatology*; Chair of EASL-CLIF Consortium
- **Prof. Claudio RONCO** (Italy) – Hemoadsorption Expert; Director, International Renal Research Institute (IRRIV), San Bortolo Hospital
- **Prof. Yu Chen** (China) – Hemoadsorption Expert; Director, Beijing Youan Hospital; Vice Chairman, Hepatology Branch, Chinese Medical Association
- **Prof. Volkan İNCE** (Türkiye) – Liver Transplantation Institute, İnönü University
- **Prof. Rakhi MAIWALL** (India) – Institute of Liver and Biliary Sciences
- **Dr. Petr PÍZA** (Czech Republic) – Deputy Head, Department of Anesthesiology, Resuscitation, and Intensive Care
- **Dr. Ilona BOBEK** (Hungary) – South-pest Central Hospital, Head of the Department of Anaesthesiology and Intensive Care
- **Prof. Marco FIORENTINO** (Italy) – Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Associate Professor of Nephrology, Department of Precision and Regenerative
- **Dr. Nancy CANEDO** (Mexico) – ICU Manager, HECMN La Raza; President of Mexican Critical Care Medicine Board
- **Dr. Ian Homer CUA** (Philippines) – Immediate Past President, Philippine Society of Gastroenterology, Head, Institute of Digestive and Liver Diseases, St. Luke's Medical Center- Bonifacio Global City
- **Dr. Zaira Molina COLLADO** (Spain) – Consultant in Intensive Care Medicine, University Hospital 12 de Octubre
- **Prof. Fernando Sánchez MORÁN** (Spain) – Head of Intensive Care Medicine, General University Hospital of Castellón
- **Dr. Panagiota GIANNOU** (Greece) – Hippokration General Hospital

- **Dr. Darja SMIRNOVA** (Latvia) – Pauls Stradiņš Clinical University Hospital
- **Prof. Jinling Dong** (China) – Beijing Youan Hospital, Capital Medical University
- **Prof. Fin Stolze Larsen** (Denmark) – Director, Department of Hepatology and Gastroenterology, Rigshospitalet, University of Copenhagen (TBD)

#### 4. Methodology and Working Groups

To ensure a structured and evidence-based approach, the expert panel will be divided into five working groups, each focusing on a specific clinical or technical domain:

1. **ALF Group** – Acute Liver Failure
2. **ACLF Group** – Acute-on-Chronic Liver Failure
3. **Liver Transplant Group** – Bridging and peri-transplant applications
4. **Other Indications Group** – Expanded applications
5. **Technical Evaluation and Monitoring Group** – Treatment parameters, safety, anticoagulation, and monitoring

Each group will develop key clinical questions and proposed consensus statements based on a predefined framework covering:

- Clinical efficacy and efficiency
- Impact on survival and transplant-free survival
- Effects on hemodynamics, neurological function, liver and renal function, and inflammatory biomarkers
- Optimal timing, sequencing, and combination strategies
- Technical parameters and safety monitoring

#### 5. Meeting Timeline and Deliverables

The consensus development process is structured across several phases to ensure thoroughness and academic rigor:

Phase	Activity	Timeline
1	Internal group preparation of questions and statements	Before April 21, 2026
2	In-person consensus meeting (Istanbul, Turkey)	April 21, 2026
3	Online meetings to refine consensus statements	June & September 2026
4	Data synthesis and manuscript drafting	End of 2026 – H1 2027
5	Journal submission	H2 2027 – 2028

**Target Journals:** High-impact hepatology journals (e.g., *Journal of Hepatology*, *Hepatology*) or critical care journals.

**Publication Format:** Expert opinion, guidance document, or consensus perspective.

## 6. Request for EASL Endorsement

The development of this Expert Perspective Consensus on DPMAS in liver disease aims to address a critical gap in clinical practice: the lack of evidence-based guidance for a technology widely used in Asia but still gaining recognition in Europe. EASL's endorsement would serve as a pivotal validation of the initiative's scientific rigor and international relevance, helping to bridge regional differences in clinical practice and foster global harmonization of standards.

EASL's support would further:

- ◆ Enhance the academic credibility of the consensus document, as a practical reference for hepatologists, intensivists, and transplant teams across Europe and beyond.
- ◆ Promote cross-regional knowledge exchange, leveraging EASL's extensive network and expertise to contextualize Asian clinical experience within the European healthcare landscape.
- ◆ Catalyze future research collaboration, as EASL's involvement would signal the importance of this topic and encourage high-quality multicenter studies in Europe.

- ◆ Ensure alignment with existing EASL guidelines, positioning this consensus as a complementary resource that addresses emerging technologies not yet covered in current recommendations.

We believe that EASL's endorsement would not only strengthen the final output but also contribute to the Association's broader mission of advancing hepatology education, research, and clinical excellence worldwide.

## **7. Contact Information**

For any questions or further discussion, please contact:

**Prof. Faouzi SALIBA**

Chair

Email: [faouzi.saliba@aphp.fr](mailto:faouzi.saliba@aphp.fr)

Affiliation: Hepato-biliary Centre and Liver Transplant Unit, France

We would be honored to receive EASL's endorsement and look forward to the opportunity to collaborate in advancing the field of artificial liver support systems.

**Thank you for your consideration.**